Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Astellas PharmaALPMF +22.99%77 Equity-to-Asset is 0.51 as of Mar. 2026, which is 16% below its 10-year median of 0.61. GuruFocus rates ALPMF with a GF Score™ of 77/100 and a GF Value™ of $14.37 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,007 Drug Manufacturers companies, Astellas Pharma ranks worse than 64.85% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Astellas Pharma's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $11,526 Mil. Astellas Pharma's Total Assets for the quarter that ended in Mar. 2026 was $22,479 Mil.
Therefore, Astellas Pharma's Equity to Asset Ratio for the quarter that ended in Mar. 2026 was 0.51.
The historical rank and industry rank for Astellas Pharma's Equity-to-Asset or its related term are showing as below:
ALPMF'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.45 Med: 0.61 Max: 0.7
Current: 0.51
During the past 13 years, the highest Equity to Asset Ratio of Astellas Pharma was 0.70. The lowest was 0.45. And the median was 0.61.
ALPMF's Equity-to-Asset is ranked worse than 64.85% of 1007
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs ALPMF: 0.51
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Astellas Pharma Equity-to-Asset Related Terms
Astellas Pharma Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Astellas Pharma's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALPMF vs LLY, JNJ, ABBV: Equity-to-Asset Comparison
For the Drug Manufacturers - General subindustry, Astellas Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astellas Pharma Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Astellas Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Astellas Pharma's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Astellas Pharma (ALPMF) has a Equity-to-Asset of 0.51 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Astellas Pharma and its competitors. This is 16% below median its historical median of 0.61. Over the past decade, Astellas Pharma's Equity-to-Asset has ranged from 0.45 to 0.70. According to the industry distribution chart, Astellas Pharma ranks #653 out of 1007 companies in the Drug Manufacturers industry, placing it in the top 64.8%.
Is Astellas Pharma's Equity-to-Asset too high?
Astellas Pharma's current Equity-to-Asset of 0.51 is 16% below median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 0.70. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Astellas Pharma's value of 0.51 is 16.4% below this industry median. Based on the distribution chart, Astellas Pharma ranks #653 out of 1007 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Astellas Pharma has a GF Score™ of 77/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Equity-to-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Astellas Pharma ranks #653 out of 1007 companies for Equity-to-Asset. This places Astellas Pharma in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Astellas Pharma's value of 0.51 is 16.4% below this benchmark. Historically, Astellas Pharma's own Equity-to-Asset has ranged from 0.45 to 0.70 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 0.61, Astellas Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,007 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Astellas Pharma's current Equity-to-Asset of 0.51 is 16.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Astellas Pharma and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Astellas Pharma's current Equity-to-Asset is 0.51, which is 16% below median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (ALPMF) is currently considered Fairly Valued. The stock's GF Value™ is $14.37, compared to a current price of $13.05 — trading 9.2% below its estimated fair value. The current Equity-to-Asset is 0.51, which is 16% below median its 10-year median of 0.61 and 16.4% below the Drug Manufacturers industry median of 0.61. Astellas Pharma's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Astellas Pharma (ALPMF), the current Equity-to-Asset is 0.51 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astellas Pharma (ALPMF) Overvalued in 2026?
Based on GuruFocus' analysis, Astellas Pharma stock appears to be undervalued.
The current stock price of $13.05 is trading 9.2% below its estimated GF Value™ of $14.37.
GuruFocus considers Astellas Pharma to be Fairly Valued.
Key valuation signals for ALPMF:
Equity-to-Asset: 0.51 (16% below median its 10-year median of 0.61)
GF Value™: $14.37 vs. price of $13.05 (9.2% below fair value)
Industry Position: 16.4% below the Drug Manufacturers median (#653 of 1007)
No single metric tells the full story. See the ALPMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
77GF Score
Get the complete analysis for ALPMF
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALPMF has been successfully added to your 
